Using flow cytometry to monitor glycoprotein IIb-IIIa activation

References

• Nurden AT, Caen JP. An abnormal platelet glycoprotein pattern in three cases of Glanzmann’s thrombasthenia. Br J Haematol. 1974;28(2):253–260.
   PubMed Web of Science ®Google Scholar
• Phillips DR, Jenkins CS, Luscher EF, Larrieu M. Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. Nature. 1975;257(5527):599–600.
   PubMed Web of Science ®Google Scholar
• Nachman RL, Leung LL. Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen. J Clin Invest. 1982;69(2):263–269.
   PubMed Web of Science ®Google Scholar
• Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983;72(1):325–338.
   PubMed Web of Science ®Google Scholar
• Parise LV, Phillips DR. Reconstitution of the purified platelet fibrinogen receptor. Fibrinogen binding properties of the glycoprotein IIb-IIIa complex. J Biol Chem. 1985;260(19):10698–10707.
   PubMed Web of Science ®Google Scholar
• Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest. 1979;64(5):1393–1401.
   PubMed Web of Science ®Google Scholar
• Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem. 1979;254(12):5357–5363.
   PubMed Web of Science ®Google Scholar
• Marguerie GA, Edgington TS, Plow EF. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem. 1980;255(1):154–161.
   PubMed Web of Science ®Google Scholar
• Peerschke EI, Zucker MB, Grant RA, Egan JJ, Johnson MM. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood. 1980;55(5):841–847.
   PubMed Web of Science ®Google Scholar
• Plow EF, Marguerie GA. Induction of the fibrinogen receptor on human platelets by epinephrine and the combination of epinephrine and ADP. J Biol Chem. 1980;255(22):10971–10977.
   PubMed Web of Science ®Google Scholar
• Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem. 1985;260(20):11107–11114.
   PubMed Web of Science ®Google Scholar
• Shattil SJ, Motulsky HJ, Insel PA, Flaherty L, Brass LF. Expression of fibrinogen receptors during activation and subsequent desensitization of human platelets by epinephrine. Blood. 1986;68(6):1224–1231.
   PubMed Web of Science ®Google Scholar
• Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood. 1987;70(1):307–315.
   PubMed Web of Science ®Google Scholar
• Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemost. 1991;65(5):467–473.
   PubMed Web of Science ®Google Scholar
• O’Toole TE, Loftus JC, Du XP, Glass AA, Ruggeri ZM, Shattil SJ, Plow EF, Ginsberg MH. Affinity modulation of the alpha IIb beta 3 integrin (platelet GPIIb- IIIa) is an intrinsic property of the receptor. Cell Regul. 1990;1(12):883–893.
   PubMedGoogle Scholar
• Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood. 1990;75(1):128–138.
   PubMed Web of Science ®Google Scholar
• Frojmovic M, Wong T. Dynamic measurements of the platelet membrane glycoprotein IIb-IIIa receptor for fibrinogen by flow cytometryII. Platelet size-dependent subpopulations. Biophys J. 1991;59(4):828–837.
   PubMed Web of Science ®Google Scholar
• Frojmovic M, Wong T, van de Ven T. Dynamic measurements of the platelet membrane glycoprotein IIb-IIIa receptor for fibrinogen by flow cytometryI. Methodology, theory and results for two distinct activators. Biophys J. 1991;59(4):815–827.
   PubMed Web of Science ®Google Scholar
• Frojmovic MM, Mooney RF, Wong T. Dynamics of platelet glycoprotein IIb-IIIa receptor expression and fibrinogen bindingII. Quantal activation parallels platelet capture in stir-associated microaggregation. Biophys J. 1994;67(5):2069–2075.
   PubMed Web of Science ®Google Scholar
• Frojmovic MM, Mooney RF, Wong T. Dynamics of platelet glycoprotein IIb-IIIa receptor expression and fibrinogen bindingI. Quantal activation of platelet subpopulations varies with adenosine diphosphate concentration. Biophys J. 1994;67(5):2060–2068.
   PubMed Web of Science ®Google Scholar
• Shattil SJ, Budzynski A, Scrutton MC. Epinephrine induces platelet fibrinogen receptor expression, fibrinogen binding, and aggregation in whole blood in the absence of other excitatory agonists. Blood. 1989;73(1):150–158.
   PubMed Web of Science ®Google Scholar
• Lindahl TL, Festin R, Larsson A. Studies of fibrinogen binding to platelets by flow cytometry: an improved method for studies of platelet activation. Thromb Haemost. 1992;68(2):221–225.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Powling MJ, Hardisty RM. Measurement of fibrinogen binding to platelets in whole blood by flow cytometry: a micromethod for the detection of platelet activation. Br J Haematol. 1990;76(3):387–394.
   PubMed Web of Science ®Google Scholar
• Zamarron C, Ginsberg MH, Plow EF. A receptor-induced binding site in fibrinogen elicited by its interaction with platelet membrane glycoprotein IIb-IIIa. J Biol Chem. 1991;266(24):16193–16199.
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Lam SC, Plow EF, Smith MA, Loftus JC, Ginsberg MH. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion. J Biol Chem. 1988;263(25):12397–12402.
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Cohen I, Plow EF, Smith MA, Roberts J, Lam SC, Ginsberg MH. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem. 1990;265(11):6346–6352.
   PubMed Web of Science ®Google Scholar
• Du XP, Plow EF, Frelinger AL 3rd, O’Toole TE, Loftus JC, Ginsberg MH. Ligands “activate” integrin aIIbb3 (platelet GPIIb-IIIa). Cell. 1991;65(3):409–416.
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Du XP, Plow EF, Ginsberg MH. Monoclonal antibodies to ligand-occupied conformers of integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J Biol Chem. 1991;266(26):17106–17111.
   PubMed Web of Science ®Google Scholar
• Kouns WC, Kirchhofer D, Hadvary P, Edenhofer A, Weller T, Pfenninger G, Baumgartner HR, Jennings LK, Steiner B. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood. 1992;80(10):2539–2547.
   PubMed Web of Science ®Google Scholar
• Kouns WC, Newman PJ, Puckett KJ, Miller AA, Wall CD, Fox CF, Seyer JM, Jennings LK. Further characterization of the loop structure of platelet glycoprotein IIIa: partial mapping of functionally significant glycoprotein IIIa epitopes. Blood. 1991;78(12):3215–3223.
   PubMed Web of Science ®Google Scholar
• Kouns WC, Wall CD, White MM, Fox CF, Jennings LK. A conformation-dependent epitope of human platelet glycoprotein IIIa. J Biol Chem. 1990;265(33):20594–20601.
   PubMed Web of Science ®Google Scholar
• Gilchrist IC, O’Shea JC, Kosoglou T, Jennings LK, Lorenz TJ, Kitt MM, Kleiman NS, Talley D, Aguirre F, Davidson C, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation. 2001;104(4):406–411.
   PubMed Web of Science ®Google Scholar
• Kasahara K, Takagi J, Sekiya F, Inada Y, Saito Y. Analysis of distribution of receptors among platelets by flow cytometry. Thromb Res. 1987;45(6):763–770.
   PubMed Web of Science ®Google Scholar
• Jackson CW, Jennings LK. Heterogeneity of fibrinogen receptor expression on platelets activated in normal plasma with ADP: analysis by flow cytometry. Br J Haematol. 1989;72(3):407–414.
   PubMed Web of Science ®Google Scholar
• Hantgan RR. An investigation of fibrin-platelet adhesive interactions by microfluorimetry. Biochim Biophys Acta. 1987;927(1):55–64.
   PubMedGoogle Scholar
• Faraday N, Goldschmidt-Clermont P, Dise K, Bray PF. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. J Lab Clin Med. 1994;123(5):728–740.
   PubMed Web of Science ®Google Scholar
• Heilmann E, Hynes LA, Burstein SA, George JN, Dale GL. Fluorescein derivatization of fibrinogen for flow cytometric analysis of fibrinogen binding to platelets. Cytometry. 1994;17(4):287–293.
   PubMedGoogle Scholar
• Xia Z, Wong T, Liu Q, Kasirer-Friede A, Brown E, Frojmovic MM. Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Br J Haematol. 1996;93(1):204–214.
   PubMed Web of Science ®Google Scholar
• Marwali MR, Hu CP, Mohandas B, Dandapat A, Deonikar P, Chen J, Cawich I, Sawamura T, Kavdia M, Mehta JL. Modulation of ADP-induced platelet activation by aspirin and pravastatin: role of lectin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress, and inside-out integrin signaling. J Pharmacol Exp Ther. 2007;322(3):1324–1332.
   PubMed Web of Science ®Google Scholar
• Su X, Mi J, Yan J, Flevaris P, Lu Y, Liu H, Ruan Z, Wang X, Kieffer N, Chen S, et al. RGT, a synthetic peptide corresponding to the integrin beta 3 cytoplasmic C-terminal sequence, selectively inhibits outside-in signaling in human platelets by disrupting the interaction of integrin alpha IIb beta 3 with Src kinase. Blood. 2008;112(3):592–602.
   PubMed Web of Science ®Google Scholar
• Shi X, Yang J, Cui X, Huang J, Long Z, Zhou Y, Liu P, Tao L, Ruan Z, Xiao B, et al. Functional effect of the mutations similar to the cleavage during platelet activation at integrin beta3 cytoplasmic tail when expressed in mouse platelets. PLoS One. 2016;11(11):e0166136.
   PubMed Web of Science ®Google Scholar
• Canault M, Ghalloussi D, Grosdidier C, Guinier M, Perret C, Chelghoum N, Germain M, Raslova H, Peiretti F, Morange PE, et al. Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleeding. J Exp Med. 2014;211(7):1349–1362.
   PubMed Web of Science ®Google Scholar
• Gralnick HR, Williams SB, McKeown L, Shafer B, Connaghan GD, Hansmann K, Vail M, Magruder L. Endogenous platelet fibrinogen: its modulation after surface expression is related to size-selective access to and conformational changes in the bound fibrinogen. Br J Haematol. 1992;80(3):347–357.
   PubMed Web of Science ®Google Scholar
• Peerschke EI. The platelet fibrinogen receptor. Semin Hematol. 1985;22(4):241–259.
   PubMed Web of Science ®Google Scholar
• Bergmeier W, Schulte V, Brockhoff G, Bier U, Zirngibl H, Nieswandt B. Flow cytometric detection of activated mouse integrin alphaIIbbeta3 with a novel monoclonal antibody. Cytometry. 2002;48(2):80–86.
   PubMedGoogle Scholar
• Ginsberg MH, Frelinger AL, Lam SC, Forsyth J, McMillan R, Plow EF, Shattil SJ. Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies. Blood. 1990;76(10):2017–2023.
   PubMed Web of Science ®Google Scholar
• Michelson AD. Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: methods and clinical applications. Blood Coagul Fibrinolysis. 1994;5(1):121–131.
   PubMed Web of Science ®Google Scholar
• Michelson AD. Flow cytometric analysis of platelets. Vox Sang. 2000;78(Suppl 2):137–142.
   PubMedGoogle Scholar
• Michelson AD, Barnard MR, Krueger LA, Frelinger AL 3rd, Furman MI. Evaluation of platelet function by flow cytometry. Methods. 2000;21(3):259–270.
   PubMed Web of Science ®Google Scholar
• Berny-Lang M, Frelinger AL 3rd, Barnard MR, Michelson AD. Flow Cytometry. In: Michelson AD, editor. Platelets. 3rd. San Diego: Elsevier/Academic Press; 2013. p. 581–602.
   Google Scholar
• Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, Shattil SJ, Randolph A, Jakubowski JA, Jennings LK, et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997;96(5):1488–1494.
   PubMed Web of Science ®Google Scholar
• Kozek-Langenecker SA, Mohammad SF, Masaki T, Kamerath C, Cheung AK. The effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood flow cytometry. Anesth Analg. 2000;90(4):808–812.
   PubMed Web of Science ®Google Scholar
• Linden MD, Frelinger AL 3rd, Barnard MR, Przyklenk K, Furman MI, Michelson AD. Application of flow cytometry to platelet disorders. Semin Thromb Hemost. 2004;30(5):501–511.
   PubMed Web of Science ®Google Scholar
• Ramstrom S, Sodergren AL, Tynngard N, Lindahl TL. Platelet function determined by flow cytometry: New perspectives? Semin Thromb Hemost. 2016;42(3):268–281.
   PubMed Web of Science ®Google Scholar
• Krueger LA, Barnard MR, Frelinger III AL, Furman MI, Michelson AD. Immunophenotypic analysis of platelets. In: Robinson JP, Darzynkiewicz Z, Dean PN, et al., editors. Current Protocols in Cytometry. New York: John Wiley & Sons; 2002. p. 1–17.
   Google Scholar
• Frelinger AL 3rd, Furman MI, Krueger LA, Barnard MR, Michelson AD. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation. 2001;104(12):1374–1379.
   PubMed Web of Science ®Google Scholar
• Munnix IC, Kuijpers MJ, Auger J, Thomassen CM, Panizzi P, Van Zandvoort MA, Rosing J, Bock PE, Watson SP, Heemskerk JW. Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation. Arterioscler Thromb Vasc Biol. 2007;27(11):2484–2490.
   PubMed Web of Science ®Google Scholar
• Sodergren AL, Ramstrom S. Platelet subpopulations remain despite strong dual agonist stimulation and can be characterised using a novel six-colour flow cytometry protocol. Sci Rep. 2018;8(1):1441.
   PubMedGoogle Scholar
• Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL 3rd, et al. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention. Am Heart J. 2003;145(2):e6.
   PubMedGoogle Scholar
• Furman MI, Krueger LA, Linden MD, Fox ML, Ball SP, Barnard MR, Frelinger AL 3rd, Michelson AD. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost. 2005;3(2):312–320.
   PubMed Web of Science ®Google Scholar
• Huskens D, Sang Y, Konings J, Van Der Vorm L, De Laat B, Kelchtermans H, Roest M. Standardization and reference ranges for whole blood platelet function measurements using a flow cytometric platelet activation test. PLoS One. 2018;13(2):e0192079.
   PubMed Web of Science ®Google Scholar
• Gresele P, Harrison P, Bury L, Falcinelli E, Gachet C, Hayward CP, Kenny D, Mezzano D, Mumford AD, Nugent D, et al. Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. J Thromb Haemost. 2014;12:1562–1569.
   PubMed Web of Science ®Google Scholar
• Michelson AD. Flow cytometry: a clinical test of platelet function. Blood. 1996;87(12):4925–4936.
   PubMed Web of Science ®Google Scholar
• Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR, Michelson AD. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest. 1996;97(4):979–987.
   PubMed Web of Science ®Google Scholar
• Escolar G, Diaz-Ricart M, Garrido M, Reverter JC, Villamor N, Sanz C, Maragall S, Castillo R, Ordinas A, Nurden AT. A variant of Glanzmann’s thrombasthenia which fails to express a GPIIb-IIIa related epitope that is recognized by a specific monoclonal antibody (C17). Br J Haematol. 1992;81(4):545–551.
   PubMed Web of Science ®Google Scholar
• Gabbeta J, Yang X, Sun L, McLane MA, Niewiarowski S, Rao AK. Abnormal inside-out signal transduction-dependent activation of glycoprotein IIb-IIIa in a patient with impaired pleckstrin phosphorylation. Blood. 1996;87(4):1368–1376.
   PubMed Web of Science ®Google Scholar
• Lozano ML, Cook A, Bastida JM, Paul DS, Iruin G, Cid AR, Adan-Pedroso R, Ramon Gonzalez-Porras J, Hernandez-Rivas JM, Fletcher SJ, et al. Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction. Blood. 2016;128(9):1282–1289.
   PubMed Web of Science ®Google Scholar
• Michelson AD. Platelet function in the newborn. Semin Thromb Hemost. 1998;24(6):507–512.
   PubMed Web of Science ®Google Scholar
• Hezard N, Potron G, Schlegel N, Amory C, Leroux B, Nguyen P. Unexpected persistence of platelet hyporeactivity beyond the neonatal period: a flow cytometric study in neonates, infants and older children. Thromb Haemost. 2003;90(1):116–123.
   PubMed Web of Science ®Google Scholar
• Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation. 2000;101(9):1013–1018.
   PubMed Web of Science ®Google Scholar
• Harder S, Klinkhardt U, Graff J, Westrup D, Kirchmaier CM, Glusa E, Mascelli MA, Marciniak SJ, Just A, Losche W, et al. In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests. Thromb Res. 2001;102(1):39–48.
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Jakubowski JA, Li Y, Barnard MR, Fox ML, Linden MD, Sugidachi A, Winters KJ, Furman MI, Michelson AD. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: influence of other blood cells, calcium, and aspirin. Thromb Haemost. 2007;98(1):192–200.
   PubMed Web of Science ®Google Scholar
• Chang H, Yanachkov IB, Michelson AD, Li Y, Barnard MR, Wright GE, Frelinger AL 3rd. Diadenosine P1, P4-tetraphosphate and its tetraphosphonate derivatives synergistically inhibit platelet activation via both P2Y1 and P2Y12. J Am Coll Cardiol. 2008;51(10):A281.
   Web of Science ®Google Scholar
• Yanachkov IB, Chang H, Yanachkova MI, Dix EJ, Berny-Lang MA, Gremmel T, Michelson AD, Wright GE, Frelinger AL 3rd. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Eur J Med Chem. 2015;107:204–218.
   PubMed Web of Science ®Google Scholar
• Gerrits AJ, Jakubowski JA, Michelson AD, Frelinger AL 3rd. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: reply. J Thromb Haemost. 2018;16(3):607–608.
   PubMed Web of Science ®Google Scholar
• Shattil SJ, Brass LF. Induction of the fibrinogen receptor on human platelets by intracellular mediators. J Biol Chem. 1987;262(3):992–1000.
   PubMed Web of Science ®Google Scholar
• O’Toole TE, Katagiri Y, Faull RJ, Peter K, Tamura R, Quaranta V, Loftus JC, Shattil SJ, Ginsberg MH. Integrin cytoplasmic domains mediate inside-out signal transduction. J Cell Biol. 1994;124(6):1047–1059.
   PubMed Web of Science ®Google Scholar
• Kashiwagi H, Schwartz MA, Eigenthaler M, Davis KA, Ginsberg MH, Shattil SJ. Affinity modulation of platelet integrin alphaIIbbeta3 by beta3- endonexin, a selective binding partner of the beta3 integrin cytoplasmic tail. J Cell Biol. 1997;137(6):1433–1443.
   PubMed Web of Science ®Google Scholar
• Hackeng CM, Huigsloot M, Pladet MW, Nieuwenhuis HK, Van Rijn HJ, Akkerman JW. Low-density lipoprotein enhances platelet secretion via integrin-alphaIIbbeta3-mediated signaling. Arterioscler Thromb Vasc Biol. 1999;19(2):239–247.
   PubMed Web of Science ®Google Scholar
• Kamae T, Shiraga M, Kashiwagi H, Kato H, Tadokoro S, Kurata Y, Tomiyama Y, Kanakura Y. Critical role of ADP interaction with P2Y12 receptor in the maintenance of alpha(IIb)beta3 activation: association with Rap1B activation. J Thromb Haemost. 2006;4(6):1379–1387.
   PubMed Web of Science ®Google Scholar
• Gingras AR, Ye F, Ginsberg MH. Reconstructing integrin activation in vitro. Methods Mol Biol. 2013;1046:1–17.
   PubMedGoogle Scholar
• Karmakar T, Mallick SK, Chakraborty A, Maiti A, Chowdhury S, Bhattacharyya M. Signature biomarkers in diabetes mellitus and associated cardiovascular diseases. Clin Hemorheol Microcirc. 2015;59(1):67–81.
   PubMed Web of Science ®Google Scholar
• Woth G, Tokes-Fuzesi M, Magyarlaki T, Kovacs GL, Vermes I, Muhl D. Activated platelet-derived microparticle numbers are elevated in patients with severe fungal (Candida albicans) sepsis. Ann Clin Biochem. 2012;49(Pt 6):554–560.
   PubMedGoogle Scholar
• Frelinger AL 3rd, Jakubowski JA, Brooks JK, Carmichael SL, Berny-Lang MA, Barnard MR, Heeney MM, Michelson AD. Platelet Activation and Inhibition iN Sickle cell disease (PAINS) study. Platelets. 2014;25(1):27–35.
   PubMed Web of Science ®Google Scholar
• Annarapu GK, Singhal R, Gupta A, Chawla S, Batra H, Seth T, Guchhait P. HbS binding to GP1balpha activates platelets in sickle cell disease. PLoS One. 2016;11(12):e0167899.
   PubMed Web of Science ®Google Scholar
• Akar S, Ozcan MA, Ates H, Gurler O, Alacacioglu I, Ozsan GH, Akkoc N, Ozkan S, Demirkan F, Onen F. Circulated activated platelets and increased platelet reactivity in patients with Behcet’s disease. Clin Appl Thromb Hemost. 2006;12(4):451–457.
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Grace RF, Gerrits AJ, Berny-Lang MA, Brown T, Carmichael SL, Neufeld EJ, Michelson AD. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood. 2015;126(7):873–879.
   PubMed Web of Science ®Google Scholar
• Smolensky Koganov E, Carmichael SL, Forde EE, Frelinger AL, Michelson AD. Platelet function in thrombocytopenic patients with chronic liver disease. Blood. 2017;130(Suppl 1):2314.
   Google Scholar
• Vinholt PJ, Hvas AM, Nielsen C, Soderstrom AC, Sprogoe U, Fialla AD, Nybo M. Reduced platelet activation and platelet aggregation in patients with alcoholic liver cirrhosis. Platelets, doi:10.1080/09537104.2017.1349308.
   Google Scholar
• Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, Tate C, Mathur K, Frelinger AL, Michelson AD. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012;119(17):4066–4072.
   PubMed Web of Science ®Google Scholar
• Takayama N, Eto K. Pluripotent stem cells reveal the developmental biology of human megakaryocytes and provide a source of platelets for clinical application. Cell Mol Life Sci. 2012;69(20):3419–3428.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Takayama N, Hirata S, Seo H, Endo H, Ochi K, Fujita KI, Koike T, Harimoto KI, Dohda T, et al. Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells. Cell Stem Cell. 2014;14(4):535–548.
   PubMed Web of Science ®Google Scholar
• Sullivan SK, Mills JA, Koukouritaki SB, Vo KK, Lyde RB, Paluru P, Zhao G, Zhai L, Sullivan LM, Wang Y, et al. High-level transgene expression in induced pluripotent stem cell-derived megakaryocytes: correction of Glanzmann thrombasthenia. Blood. 2014;123(5):753–757.
   PubMed Web of Science ®Google Scholar
• Bandura DR, Baranov VI, Ornatsky OI, Antonov A, Kinach R, Lou X, Pavlov S, Vorobiev S, Dick JE, Tanner SD. Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal Chem. 2009;81(16):6813–6822.
   PubMed Web of Science ®Google Scholar
• Majonis D, Herrera I, Ornatsky O, Schulze M, Lou X, Soleimani M, Nitz M, Winnik MA. Synthesis of a functional metal-chelating polymer and steps toward quantitative mass cytometry bioassays. Anal Chem. 2010;82(21):8961–8969.
   PubMed Web of Science ®Google Scholar
• Ornatsky O, Bandura D, Baranov V, Nitz M, Winnik MA, Tanner S. Highly multiparametric analysis by mass cytometry. J Immunol Methods. 2010;361(1–2):1–20.
   PubMed Web of Science ®Google Scholar
• Bendall SC, Nolan GP, Roederer M, Chattopadhyay PK. A deep profiler’s guide to cytometry. Trends Immunol. 2012;33(7):323–332.
   PubMed Web of Science ®Google Scholar
• Blair TA, Michelson AD, Frelinger AL. Mass cytometry of platelets: simultaneous functional and phenotypic analysis of multiple surface markers in healthy subjects and patients with inherited platelet disorders reveals novel platelet sub-populations. Blood. 2017;130(Suppl 1):2311.
   Google Scholar
• Frelinger AL 3rd, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006;113(25):2888–2896.
   PubMed Web of Science ®Google Scholar